JHU Drug Access & Affordability Initiative

Official account of The Johns Hopkins Drug Access & Affordability Initiative • Drug Pricing Research Group @JohnsHopkinsSPH • Funding from @Arnold_Ventures

[JHU Drug Access & Affordability Initiative @JHDAAI_Research]

Guess what? The Johns Hopkins Drug Access & Affordability Initiative @JohnsHopkinsSPH is joining the social media game! We'll be featuring drug policy research from our renowned team members. From topics ranging from #COVID19 testing to biosimilars, we've got them all!

[Matthew Eisenberg @MattDEisenberg]

Very excited to see this paper out in @AJMC_Journal! We descriptively looked at employer market power across the U.S. and tried to see if employers had scope to take a more direct role in health care price negotiations. Short answer-> they lack the market power to do this!

[Mark Meiselbach @Mark_Meiselbach]

New paper out in @AJMC_Journal, led by @MattDEisenberg and described in this thread. In short, we find that employers generally lack sufficient market power to influence hospital prices in their market.

[BSPH / HPM @BSPH_HPM]

HPM faculty @MattDEisenberg, @GeBaiDC, @aditipsen, and Gerard Anderson, and PhD candidate @Mark_Meiselbach published a new @AJMC_Journal paper finding that across the U.S. self-insured employers lack market power to negotiate prices for hospital services. https://t.co/AXi6M6mnmt

[JAMA Internal Medicine @JAMAInternalMed]

New from @JHDAAI_Research @JohnsHopkinsSPH: half of #prescription drug copay offsets come from pharmacies and PBMs, not drug companies, offsets reduce out-of-pocket costs but concentrated in small number of drugs and may not reach those most in need https://t.co/brRgVysoOY

[Mark Meiselbach @Mark_Meiselbach]

New paper out with @MattDEisenberg, @GeBaiDC, @aditipsen, and Jerry Anderson in @MCRRSage. We investigate the relationship between labor market concentration and health insurance premium contributions in employer-sponsored insurance markets. (1/4) https://t.co/9sf08D60wF

[Ge Bai @GeBaiDC]

Orphan Drug Act @AISHealth

[JHU Drug Access & Affordability Initiative @JHDAAI_Research]

Check out this recent article from @JHDAAI_Research team members published by @sciencedirect ⤵️

[Mike DiStefano @DiStefano_MJ]

My recent work with @soyeonkang_JH @Farah_Y_ @christianm62 and Gerard Anderson is now available through @ISPORJournals. @JHDAAI_Research @JHSPH_HPM

We examined the added therapeutic benefit of "ultra-expensive drugs". (1/4)

https://t.co/TimNhjL1jJ

[JHU Drug Access & Affordability Initiative @JHDAAI_Research]

🚨 New article in @AJMC_Journal 🚨

Check out @bryanhambley1, @KellyAnders0n, @aditipsen, and others talk about changes in utilization of various intravenous iron in the Medicare population ⤵️

https://t.co/4spjf0r4N1

[JHU Drug Access & Affordability Initiative @JHDAAI_Research]

🚨Featured Friday🚨

@jodi_segal is the co-director of the Center for Drug Safety and Effectiveness @JohnsHopkins and an associate director of the Center for Health Services and Outcomes Research. She is a practicing internist, epidemiologist, and health services researcher.

[JHU Drug Access & Affordability Initiative @JHDAAI_Research]

Ten years after Congress established a special pathway, lower cost versions of brand-name biologics were approved for only 9 reference products. Our team found that meeting requirements for equivalence was time-consuming and costly, and some testing might not be needed.

[JHU Drug Access & Affordability Initiative @JHDAAI_Research]

🚨 New article in @JAMAInternalMed from researchers @JHDAAI_Research!

"Assessment of Availability, Clinical Testing, and US Food and Drug Administration Review of Biosimilar Biologic Products"

https://t.co/TtXTAvy0t9

[JHU Drug Access & Affordability Initiative @JHDAAI_Research]

Kelly Anderson is a PhD candidate in @JHSPH_HPM. She studies Medicare insurance design, including physician-administered (Part B) drug spending and utilization. When she is not working, she is outside hiking and climbing. Follow her @KellyAnders0n!

#FeaturedFriday

[Ge Bai @GeBaiDC]

https://t.co/a3tOWuNjt9 study site: https://t.co/xwvBLBtAL1 @Mark_Meiselbach @Alexruoff @bloomberggov

[JHU Drug Access & Affordability Initiative @JHDAAI_Research]

This week's #FeaturedFriday is Dr. Antonio Trujillo! He is an Associate Professor @JohnsHopkinsIH and member @JHDAAI_Research. His research interest includes fairness in prescription drug prices, anti-competitive behaviors in the generic drugs markets, and access to biosimilars.

[JHU Drug Access & Affordability Initiative @JHDAAI_Research]

Thanks for the shoutout📣

[Mike DiStefano @DiStefano_MJ]

Give this account a follow if you are interested in drug policy research! Will be posting the latest research from Gerard Anderson et al. @JHSPH_HPM

[Mark Meiselbach @Mark_Meiselbach]

Across states, we find that Arkansas, Louisiana, Missouri, and New Mexico had high average charges for both tests. Overall, 8% and 14% of diagnostic and antibody tests, respectively, exceed Medicare's payment rate by at least one standard deviation. (4/4)

[Mark Meiselbach @Mark_Meiselbach]

The most common facility type was independent laboratories for both tests (50% of diagnostic tests, 97% of antibody tests). The average charge across facilities for were approximately $144 and $64, respectively, but there is substantial variation across facility types. (3/4)

[Mark Meiselbach @Mark_Meiselbach]

Recent media attention has focused on high charges for COVID-19 tests. We conduct the first nationwide study of charges for diagnostic and antibody tests. We assess variation in charges across facility types and across states among 500k+ testing charges from 3/19 to 7/19 (2/4)

[Matthew Eisenberg @MattDEisenberg]

Important new research letter by my great colleagues @Mark_Meiselbach @GeBaiDC and Jerry Anderson

[JHU Drug Access & Affordability Initiative @JHDAAI_Research]

“[A] handful of hospitals and independent laboratories have charged exorbitant fees that are more than 5x Medicare’s prices. These high charges may deter patients from seeking testing which could lead to further spread of the virus.”

[JHU Drug Access & Affordability Initiative @JHDAAI_Research]

🚨New @JournalGIM article titled "Charges of COVID-19 Diagnostic Testing and Antibody Testing Across Facility Types and States." Project led by @Mark_Meiselbach and contributions from @GeBaiDC and others @JHDAAI_Research!

https://t.co/PlO07hq4mU